IN
INBX.US Inhibrx Biosciences, Inc.
- Market cap
- USD 1.23B
- P/E
- -
- P/B
- 7.41x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is INBX.US undervalued?
Graham numberThe Graham number of Inhibrx Biosciences, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Inhibrx Biosciences, Inc. fundamental analysis
No fundamental analysis for Inhibrx Biosciences, Inc. yet.
Inhibrx Biosciences, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tum…
Full company profileInhibrx Biosciences, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Inhibrx Biosciences, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.67M | 8.39M | 8.60M | 9.09M | 12.8M | 7.13M | 2.19M | 1.80M | 200K | 1.30M | 0.00 |
| Gross Profit | -10.3M | -17.1M | -24.9M | -38.8M | -60.7M | 4.44M | -108M | 609K | -2.09M | -1.18M | - |
| Operating Income | -12.1M | -19.7M | -29.5M | -41.0M | -67.4M | -76.7M | -129M | -219M | -331M | -135M | -126M |
| EBITDA | -11.9M | -19.3M | -28.8M | -39.8M | -66.4M | -75.4M | -126M | -207M | 1.70B | -125M | -120M |
| Net Income | -8.27M | -19.4M | -31.2M | -51.4M | -76.1M | -81.8M | -145M | -241M | 1.69B | -140M | -140M |
| EPS | -0.23 | -0.68 | -1.15 | -1.41 | -3.01 | -2.15 | -3.62 | -5.12 | 117 | -9.04 | -8.95 |
| Balance Sheet | |||||||||||
| Total Assets | 21.3M | 17.2M | 9.98M | 26.5M | 144M | 150M | 291M | 308M | 181M | 146M | 154M |
| Total Liabilities | 20.0M | 39.7M | 67.6M | 120M | 68.3M | 98.1M | 233M | 264M | 47.2M | 138M | 207M |
| Shareholders' Equity | -9.25M | -28.8M | -57.6M | -93.6M | 75.5M | 52.4M | 58.1M | 43.5M | 134M | 7.99M | -53.0M |
| Cash & Short-term Investments | 20.0M | 13.5M | 2.10M | 11.5M | 129M | 131M | 274M | 278M | 153M | 124M | 133M |
| Total Debt | 18.9M | 14.7M | 9.49M | 41.7M | 37.5M | 72.1M | 207M | 210M | 8.05M | 107M | 5.34M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -18.1M | -18.8M | -23.1M | -32.1M | -48.0M | -80.3M | -115M | -193M | -194M | -130M | -136M |
| Capital Expenditure | 215K | 1.34M | 1.43M | 1.81M | 1.36M | 864K | 686K | 4.59M | 2.60M | 31.0K | 54.0K |
| Free Cash Flow | -18.3M | -20.1M | -24.5M | -33.9M | -49.3M | -81.2M | -116M | -198M | -197M | -130M | -136M |
| Ratios | |||||||||||
| ROE | - | - | - | - | -100.9% | -156.1% | -250.1% | -554.8% | 1,263.3% | -1,752.2% | - |
| ROA | -38.9% | -112.7% | -312.1% | -194.0% | -53.0% | -54.3% | -49.9% | -78.4% | 933.6% | -95.6% | -90.9% |
| Net Profit Margin | -124.0% | -231.7% | -362.6% | -565.3% | -594.3% | -1,147.6% | -6,625.3% | -13,408.9% | 843,786.0% | -10,773.5% | - |
| Debt to Equity | - | - | - | - | 0.50x | 1.38x | 3.57x | 4.83x | 0.06x | 13.39x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Inhibrx Biosciences, Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | USD 828K | 0.03 | - |
| 2017 | USD 1.38M | 0.05 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Inhibrx Biosciences, Inc.
- Insiders 23.31%
- Institutions 76.69%
- Public & others 0.00%
- Shares outstanding 14.7M
- Free float 9.16M
Top funds holding INBX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 415K | 2.82% | +12.26% | Sep 2026 |
| American Funds SMALLCAP World A | 353K | 2.40% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 349K | 2.37% | +2.69% | Oct 2026 |
| iShares Russell 2000 ETF | 241K | 1.64% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 104K | 0.71% | 0.00% | Aug 2026 |
| iShares Biotechnology ETF | 85.7K | 0.58% | -0.19% | Oct 2026 |
| iShares Russell 2000 Growth ETF | 72.8K | 0.49% | -0.38% | Oct 2026 |
| Eventide Healthcare & Life Sciences I | 61.5K | 0.42% | 0.00% | Jun 2026 |
| Vanguard Russell 2000 ETF | 55.3K | 0.38% | +1.23% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 52.5K | 0.36% | +0.18% | Oct 2026 |
| First Trust Small Cap Gr AlphaDEX® ETF | 50.5K | 0.34% | +0.43% | Oct 2026 |
| Invesco Dorsey Wright SmallCap Momt ETF | 44.9K | 0.31% | -0.54% | Oct 2026 |
| Fidelity Extended Market Index | 44.8K | 0.30% | -5.10% | Sep 2026 |
| Fidelity Enhanced Small Cap Core ETF | 33.2K | 0.23% | +0.27% | Oct 2026 |
| Invesco Dorsey Wright Healthcare MomtETF | 31.6K | 0.21% | 0.00% | Oct 2026 |
| Vanguard US Momentum Factor ETF | 24.9K | 0.17% | -9.75% | Sep 2026 |
| Schwab Small Cap Index | 23.1K | 0.16% | -0.22% | Sep 2026 |
| VictoryShares US Sm Md Cp Val Momt ETF | 23.0K | 0.16% | +0.29% | Oct 2026 |
| Stt Strt®SPDR®S&PKenshoNwEcosComposETF | 21.6K | 0.15% | +0.07% | Oct 2026 |
| Vanguard Health Care ETF | 21.2K | 0.14% | +0.11% | Sep 2026 |
Top institutions holding INBX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Morgan Stanley - Brokerage Accounts | 1.31M | 8.89% | +3.56% | Jun 2026 |
| Perceptive Advisors LLC | 1.30M | 8.82% | -10.05% | Jun 2026 |
| Sanofi | 1.16M | 7.87% | 0.00% | Sep 2026 |
| Viking Global Investors LP | 1.12M | 7.64% | -21.82% | Jun 2026 |
| HighTower Advisors, LLC | 871K | 5.92% | +0.04% | Jun 2026 |
| Bank of America Corp | 841K | 5.72% | +2,473.63% | Jun 2026 |
| BlackRock Inc | 826K | 5.61% | +3.39% | Jun 2026 |
| Schonfeld Strategic Advisors LLC | 698K | 4.74% | +173.75% | Jun 2026 |
| State Street Corp | 640K | 4.35% | +16.27% | Jun 2026 |
| Vanguard Capital Management, LLC | 492K | 3.35% | +1.24% | Jun 2026 |
| Woodline Partners LP | 401K | 2.72% | +4.28% | Jun 2026 |
| Capital Research Global Investors | 362K | 2.46% | -0.16% | Sep 2026 |
| The Goldman Sachs Group Inc | 338K | 2.30% | +255.70% | Jun 2026 |
| Partner Fund Management LP | 308K | 2.10% | +0.97% | Jun 2026 |
| Sofinnova Ventures | 303K | 2.06% | -25.35% | Jun 2026 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 272K | 1.85% | +59.17% | Jun 2026 |
| Parkman Healthcare Partners LLC | 257K | 1.75% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 256K | 1.74% | +10.65% | Jun 2026 |
| First Turn Management LLC | 165K | 1.12% | 0.00% | Jun 2026 |
| Millennium Management LLC | 147K | 1.00% | -55.10% | Jun 2026 |
Inhibrx Biosciences, Inc. company profile
- Company name
- Inhibrx Biosciences, Inc.
- Ticker
- INBX.US
- Exchange
- USA Stocks
- Listed since
- May 29, 2024
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 109
- Fiscal year end
- December
- Address
- 11025 North Torrey Pines Road, La Jolla, CA, United States, 92037
- Phone
- 858 795 4220
- Website
- inhibrx.com
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Inhibrx Biosciences, Inc. management
10- Mr. Mark Paul LappeFounder, CEO & Chairman · born 1967
- Mr. David J. Matly M.B.A.President · born 1986
- Ms. Kelly Devine Deck B.S., CPA, M.S.Executive VP, CFO & Treasurer · born 1980
- Ms. Bonne Adams M.B.A.Vice President of Operations · born 1977
- Ms. Kate Burke CPA, M.B.A.Vice President of Accounting
- Dr. Ashraf Amanullah Ph.D.Executive VP & Chief Technical Operations Officer · born 1968
- Dr. Carlos Bais Ph.D.EVP & Chief Scientific Officer
- Ms. Leah Pollema J.D.VP, General Counsel & Corporate Secretary
- Mr. Sean FlanaganVP of Sales
- Dr. Josep Garcia Ph.D.Executive VP & Chief Clinical Development Officer